Posts tagged with ‘patents’
Earlier this week, six research universities announced a set of shared principles for increasing access to new medicines in poor countries. Boston University, Brown, Harvard, the Oregon Health and Science University, the University of Pennsylvania, and Yale joined the Association of University Technology Managers Monday in releasing the statement, which aims to guide licensing decisions [...]
A U.S. District Court judge ruled Monday that a gene patent lawsuit filed against the Patent and Trademark Office could move forward. At issue are patents exclusively licensed by Myriad Genetics for the BRCA1 and BRCA2 genes. Mutations of the genes are strongly linked to significant risks of breast cancer. The suit, lead by the [...]
Controversies over gene patents often ignore the lack of evidence that they impede basic research. The more important concern may be the negative impact of the push to commercialize science.
“Open innovation” challenges the assumptions made by university technology transfer offices about maximizing the value of their intellectual property.
Patenting unmodified genes rewards discovery, not invention. We must prohibit the process and invalidate all claims to unmodified genes to facilitate more open science.
A quick glance at a couple early takes on R&D funding in President Obama’s budget request outline for FY2010:
Science Insider: NIH details are sketchy, but include increases; NSF would see 8.5 percent bump; more for scientific facilities though DOE’s Office of Science; earth science research funding and Orion money for NASA; 37.5 percent increase for [...]
Inventions are being created at an ever-increasing pace and have grown increasingly complex, but the rules governing patents have not seen substantial change in decades. As a result, the system is bogged down, hampering investment and job creation. Here’s how to fix things.
By far, the most significant and destabilizing change in the patent environment since 2003 has been the dramatic increase in the growth, financing, and patent acquisitions of so called non-practicing entities, or “patent trolls.”
At the end of last week, Reuters reported that the European Patent Office issued its final ruling rejecting a patent application for the stem cell technology based on the work of James Thomson of the University of Wisconsin. Filed in 1995 by the Wisconsin Alumni Research Foundation, the patent, according to the EPO release “describes a method for obtaining embryonic stem cell cultures from primates, including humans.”
Rep. Bill Foster talks about the balance between commercial science and basic long-term research, the importance of math and science education, and the need for scientific reasoning as the basis of policy discussions.
On Tuesday, a Virginia district court rejected new U.S. Patent and Trademark Office rules intended to rein in the current patent application backlog. The ruling comes as a relief to companies involved in technically complex industries, especially biotechnology and pharmaceutical firms.
Bush exemption for Navy sonar use; farmer loses to Monsanto; SLAC loses to budget; Japan hikes budget for stem cell research; Supreme Court opening arguments for patent case.
NASA has a new face on the web; the NIH says gene therapy wasn’t the cause of death in a recent trial; open-source standards and net neutrality can improve global health; and more.
The Guardian reported this past weekend that J. Craig Venter will soon announce that he has created artificial life. But even his spokesperson is saying that’s not the whole story.
